Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431543 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
A Phase 2 study, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT05431543 is a Phase 2 study that has completed, run by LENZ Therapeutics. The registered enrollment target is 59 participants.
The verdict
NCT05431543, a Phase 2 study, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Interventions
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine ophthalmic solution
- DRUG Vehicle proprietary ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-08-06 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05431543
The ClinicalTrials.gov registry entry for NCT05431543 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aceclidine+Brimonidine combination ophthalmic solution is the first listed.
NCT05431543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05431543 about?
NCT05431543 is a clinical study titled "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia". To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
What is the current status of trial NCT05431543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2022-08-06. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT05431543?
The interventions under investigation include: Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine ophthalmic solution (DRUG), Vehicle proprietary ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05431543?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.